Piamprilizumab (AK105) Combined With Radiotherapy for Neoadjuvant Treatment of Soft Tissue Sarcoma
The primary objective of this study was to evaluate the safety and efficacy of paamprilimab combined with radiotherapy for neoadjuvant treatment of soft tissue sarcoma. The primary endpoint was pathological complete response rate (CPR).
Soft Tissue Sarcoma
DRUG: Piamprimab (AK105)
Pathological complete response rate, From the beginning of treatment to the completion of surgery, From the start of treatment to surgery at week 12
Progression-free survival, From the start of treatment to the progression of the disease, It takes about 12 weeks from the start of treatment to surgery|Overall survival, From the beginning of treatment to death, 0 to 120 months
31 patients with stage I, II, and III resectable soft tissue sarcoma were enrolled in this study at the Bone and soft Tissue Ward 1 of Henan Cancer Hospital. The main objective of this study was to evaluate the safety and efficacy of paamprimab combined with radiotherapy for neoadjuvant treatment of soft tissue sarcoma. The primary endpoint of this study was pathological complete response rate (CPR).